explore allergenis news and events
September 10, 2022 ・ Austin American-Statesman
New test can show just how allergic your kids might be to peanuts
New test from the medical testing company Allergenis. The test maps epitopes to figure out just how allergic a person is to peanuts.
September 7, 2022 ・ Business Wire
New Blood Test Delivers Highly Accurate Threshold Assay That Enhances Clinical Management for Peanut Allergy
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy
August 24, 2022 ・ Politico
Promise and peril in the health care metaverse
Some 400 health care patents have a connection to the metaverse, the immersive realm that blends virtual and physical reality…
August 22, 2022 ・ GlobeNewswire
LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis
Strategic partnership enables direct-to-consumer food allergy clinic to provide convenient access to crucial peanut allergy threshold information.
August 3, 2022 ・ Allergic Living
New Peanut Allergy Test Reveals if Trace Amounts Risky or Not
Skin and blood tests to diagnose peanut allergy are known to have a high rate of false positives – as much as 50 percent. This leads to many people being wrongly diagnosed as allergic, and to a life of strict peanut avoidance.
Jun 15, 2021 ・ Allergic Living
Epitope Mapping Test Diagnoses Peanut Allergy With Over 90% Accuracy
A blood test called “epitope mapping” accurately predicted peanut allergy 93 percent of the time, a recent study finds.
Jun 15, 2021 ・ PR Newswire
New Life-Changing Test for Patients Diagnosed With Peanut Allergy
AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders including...
Jun 10, 2021 ・ PR Newswire
AllerGenis to Present at Institute for the Advancement of Food and Nutrition Sciences Annual Meeting
AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders initially...
April 6, 2021 ・ Global AgInvesting
15 MINUTES WITH… JIM GARNER, CEO OF ALLERGENIS
According to a recent McKinsey report, more than 30 million people (5.6 million are children) in the U.S. have been diagnosed with food allergies…
January 11, 2021 ・ Global AgInvesting
AllerGenis Allergy Diagnostic Company to Present Significant Milestones at the Biotech Showcase(TM) 2021
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies today announced that CEO Jim Garner will be speaking at the Biotech Showcase™ 2021, providing an on-demand company presentation.
Nov 13, 2020 ・ PR Newswire
AllerGenis and Partners Present Positive Precision Medicine Data on Tracking Peanut-Allergy Desensitization Therapy at ACAAI Virtual 2020 Annual Scientific Meeting
Each year in the U.S. 200,000 people require emergency medical care for allergic reactions to food. Annual incidence of accidental exposures...
June 24, 2020 ・ Business Wire
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology
AllerGenis LLC, a data-driven precision diagnostics company focused on food allergies, today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAPTM Pean...
June 04, 2020 ・ Business Wire
AllerGenis Announces Presentations at EAACI Digital Congress 2020
Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtua...
January 13, 2020 ・ Proactive
AllerGenis aiming to change the way food allergies are diagnoseD
AllerGenis CEO Jim Garner joined Proactive at the Biotech Showcase 2020 in San Francisco.
January 08, 2020 ・ BusinessWire
AllerGenis to Present at the 38th Annual J.P. Morgan Healthcare Conference
AllerGenis, a data-driven precision diagnostics company focused on food allergies, today announced that CEO Jim Garner will be presenting during the Biotech Showcase at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
December 23, 2019 ・ BusinessWire
New Research Demonstrates Clinical Viability of Epitope Mapping Technology Platform for Food Allergy Diagnosis
AllerGenis, a data-driven precision diagnostics company focused on food allergies, this week reported research results in Scientific Reports from Nature, in preparation for the clinical launch of its bead-based epitope mapping diagnostic platform.
January 16, 2019 ・ BusinessWire
AllerGenis Granted Rights to Develop and Market Its Precision Food Allergy Diagnostic Using Luminex xMAP® Technology
Data-driven food allergy diagnostics company, AllerGenis, LLC today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX)
October 30, 2018 ・ Mount Sinai
Mount Sinai and AllerGenis, LLC Announce Partnership to Bring Novel, Precision Diagnostics to Food Allergy Patients
AllerGenis, LLC, a data-driven diagnostic company, announced a partnership agreement with Mount Sinai Health System to develop and commercialize technology for improved food allergy detection and patient management.